Proposals from Greiner Bio-One to Vigmed's Annual General Meeting 2017
On 2 June 2017, it was announced that the Nomination Committee of Vigmed, in view of Vigmed's new ownership structure, will not submit any proposals to the Annual General Meeting 2017 and that Greiner Bio-One GmbH ("GBO") as new majority shareholder would revert with proposals. GBO has now notified its proposals to Vigmed.
GBO proposes the following to the Annual General Meeting of Vigmed to be held on 20 June 2017.
Item 2: Election of chairman of the meeting
Proposal to elect Ola Lidström as the chairman of the Annual General Meeting.
Item 13: Determination of the number of board members to be elected by the meeting
Proposal to elect four board members, without any deputy board members, for the time until the end of the next annual general meeting.
Item 14: Determination of fees for the board members and the auditors
Proposal that no remuneration should be paid to the board members for the time until the end of the next annual general meeting. Proposal that fees to the auditors, for the time until the end of the next annual general meeting, should be paid according to current invoicing approved by the company.
Item 15: Election of members of the board of directors and chairman of the board of directors
Proposal to elect Rainer Perneker, Manfred Buchberger, Georg Heftberger and Yaron Navon as board members, and Rainer Perneker as chairman of the board, for the time until the end of the next annual general meeting.
Summary of biographies for the proposed board members:
Education: Executive MBA from Danube University Krems.
Current Assignment: CEO at Greiner Bio-One International GmbH.
Previous Assignments: President at Greiner Bio-One North America, Business Manager International Operations at Greiner Bio-One GmbH, as well as Head of IT at Greiner Bio-One GmbH.
Education: MBA in Global Marketing Management from Johannes Kepler University Linz.
Current Assignments: CEO Preanalytics at Greiner Bio-One GmbH (Austria), Greiner Bio-One Suns Co., LTD, China, and Greiner Bio-One Turkey LTD, and CEO at Greiner Bio-One Vacuette Switzerland GmbH.
Previous Assignments: Deputy Manager and Sales Director at Stalltechnik Braeuer GmbH, Head of Investment Consulting, as well as Authorized Signatory at Raiffeisenbank Haidershofen.
Education: Master’s Degree in Business and Economics from Johannes Kepler University Linz.
Current Assignments: CFO Greiner Bio-One GmbH (Austria) and Greiner Bio-One GmbH (Germany).
Previous Assignments: Group Strategy and Development at Greiner Holding AG, Assistant to the Board at Greiner Holding AG, Strategic Sales at Engel Austria GmbH and SAP/ERP-Management Outbound Logistics at Engel Austria GmbH.
Education: BA in Middle Eastern History and Conflicts from Israels State University.
Current Assignment: CEO at Lambra S.A.
Previous Assignments: CEO at Vacuette España S.A. and Metaor Business Services S.A., President at Enfa S.A. and Diplomat at the Israeli Embassy.
Item 16: Election of auditor
Proposal to re-elect the registered accounting firm Öhrlings PricewaterhouseCoopers AB as auditor for the time until the end of the next annual general meeting.
Item 18: Resolution regarding Nomination Committee for the Annual General Meeting of 2018
Proposal to resolve that the company should not have a Nomination Committee in view of the company's ownership structure.
For further information contact:
Chairman of the Board Sten Dahlborg, +46 708-369 419
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG). Remium Nordic AB is the Company’s Certified Advisor.Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor